To assess the potential contribution of ErbB receptors on paclitaxel resistance in ovarian cancer, silencing RNAs (siRNA) were used to knockdown expression of EGFR, ERBB2, and ERBB4 in the control and PacR cells (S1 and S3 Figs). Here, ERBB2 is linked to ovarian cancer.